Diametric Capital’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding BBIO
Diametric Capital's BBIO Position: Q3 2026 in Review
Diametric Capital reduced its BridgeBio Pharma (BBIO) stake by 9.3% in Q3 2026, selling an estimated $67K and leaving 8,435 shares worth $555K. The position accounts for 0.05% of the portfolio, ranked #342.
Diametric Capital first reported a position in BBIO in Q2 2024 and has held it in 3 quarters since. The position peaked at $692K in Q2 2026. 471 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.
- Diametric Capital held 8,435 shares of BridgeBio Pharma worth $555K as of Q3 2026.
- Diametric Capital sold 860 BridgeBio Pharma shares in Q3 2026, an estimated $67K.
- BridgeBio Pharma made up 0.05% of Diametric Capital's portfolio in Q3 2026, its #342 holding.
- Diametric Capital first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 3 quarters since.
- Diametric Capital's BridgeBio Pharma position peaked at $692K in Q2 2026.
- 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.
Based on Diametric Capital's 13F filing for Q3 2026, filed 16 Nov 2026.